## RMD: ResMed Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_20 -2.6% below STRENGTH zone (4.0-10.0%); PEG 1.58 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge. Caution: declining volume (42% of avg).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($234.39)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_20 falling below -5% or breaking key support

### News

- **Articles:** 4
- **Sentiment:** Bullish (Bullish: 1, Bearish: 0)

**1. ResMed Inc. (NYSE:RMD) Given Average Rating of "Moderate Buy" by Analysts**
- Source: MarketBeat | 20251225T230833 | Somewhat-Bullish | Relevance: 100%
- Seventeen analysts have given ResMed Inc. (NYSE:RMD) an average rating of "Moderate Buy," with a consensus 12-month target price of $296.09. Insiders have sold 22,662 shares worth approximately $5.95 million in the last quarter, reducing their ownership to 0.65%. The company recently surpassed quarterly estimates with revenues up 9.1% year-over-year, and it offers an annual dividend of $2.40, yielding about 1.0%.

**2. Swedbank AB Increases Stock Position in ResMed Inc. $RMD**
- Source: MarketBeat | 20251224T131842 | Somewhat-Bullish | Relevance: 100%
- Swedbank AB significantly increased its stake in ResMed Inc. ($RMD) by 25.4% in the third quarter of 2025, now owning 542,711 shares valued at approximately $148.56 million. ResMed reported a strong quarterly earnings beat with $2.55 EPS against an expected $2.49, and revenue of $1.34 billion, marking a 9.1% year-over-year increase. The company also announced a quarterly dividend of $0.60 per share, representing a 1.0% yield.

**3. Vagus Nerve Stimulators Market Industry Analysis 2025-2032**
- Source: openPR.com | 20251226T121058 | Somewhat-Bullish | Relevance: 63%
- The Vagus Nerve Stimulators Market is projected to grow from USD 667.4 million in 2025 to USD 1,293.1 million by 2032, exhibiting a CAGR of 9.9%. This study provides insights into market dynamics, segmentation by type, application, and region, and profiles key companies such as LivaNova PLC and electroCore Inc. The report highlights strategic coverage of investment hotspots, regional trends, and emerging segments to aid decision-makers.

**4. Diabetes Management Apps Market to Reach USD 9.90 Billion by 2033**
- Source: openPR.com | 20251224T091005 | Bullish | Relevance: 58%
- The global Diabetes Management Apps Market, valued at US$ 1.37 billion in 2024, is projected to reach US$ 9.90 billion by 2033, growing at a CAGR of 24.7%. This growth is driven by increasing diabetes prevalence, smartphone adoption, and integration of AI/ML, with North America leading the market. Key players like Welldoc, Omada Health, and Glooko are advancing the sector through innovative solutions and strategic partnerships.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 0, Lowers: 2)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-18 | Stifel | $260 | $270 | -4% |
| 2025-12-16 | Baird | $275 | $300 | -8% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-18 | Stifel | main | Hold |
| 2025-12-16 | Baird | down | Neutral |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **MIXED** |
| Buys | 16 ($9.01M) |
| Sells | 17 ($5.01M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 37.0% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 3 / 6 |

**Top Holders:**
- Vanguard Group Inc: 13.1% (+1.6%)
- Blackrock Inc.: 8.4% (-1.3%)
- State Street Corpora: 4.5% (-1.0%)
- Bank Of New York Mel: 3.1% (-9.8%)
- Geode Capital Manage: 2.9% (+0.9%)

### Key Risks

1. Insider selling cluster: $5.0M in recent transactions.
2. Elevated short interest (8.3%): bears positioning against stock.
3. Market regime shift could impact momentum names disproportionately.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 1.58 elevated, pricing in significant growth expectations. Quality metrics strong (ROE 25%, ROA 14%, margin 27%). Balance sheet: strong liquidity (2.9x), low leverage (D/E 0.36). Analyst sentiment negative (2 target cuts vs 0 raises). Institutional flow bullish (3 buying vs 6 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $35.7B |
| Beta | 0.87 |
| 52W Range | $199.92 - $293.81 |
| Short Interest | 8.3% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.58 |
| Forward P/E | 20.4 |
| Current P/E | 22.5 |
| YoY Growth | 10.3% |
| EPS Direction | STABLE |

### Technicals

MRS_20 stable at -2.6% (minimal 5-day change). Below STRENGTH zone by 6.6pp (needs >4.0% for momentum thesis). Underperforming sector by 3.1pp, stock-specific weakness. Below SMA200 (0.96x), long-term trend not supportive. RSI neutral at 43. Volume at 42% of 20MA suggests lack of conviction. OFD pattern: +SUL (Resistance test).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | -2.60% (CS: 21) | Weak |
| RSI_14 | 42.6 | Neutral |
| MACD Histogram | -0.31 | Bearish |
| vs SMA20 | 0.983x | Below |
| vs SMA50 | 0.971x | Below |
| vs SMA200 | 0.964x | Below |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $244.87
- **Stop Loss:** $234.39 (4.3% risk)
- **Target:** $255.35 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 125
- **Position Value:** $30,608.75
- **Portfolio %:** 30.61%
- **Risk Dollars:** $1,320.00
- **Risk Per Trade:** 1.32%
- **Modifiers:** L1 110% | L2 120% | Combined 1.32x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.10x |
| L2 Sector | TREND (Zone A) | 1.20x |

*NORMAL regime with selective risk appetite amid holiday trading. VIX at extreme lows (13.6) signals complacency while positive yield curve (+59bps) and stable economic data support continuation. Focus on quality names with AI/infrastructure exposure while monitoring January volatility reset.*

### Earnings

**Next:** 2026-02-05 (Est: $2.71)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $2.50 | $2.55 | +2.0% |
| 2025Q2 | $2.48 | $2.55 | +2.8% |
| 2025Q1 | $2.36 | $2.37 | +0.4% |
| 2024Q4 | $2.31 | $2.43 | +5.0% |

---
*RULE-based L3 | 2026-01-06 16:38 | MRS_20*